T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Garfall, Alfred L., Dancy, Ehren K., Cohen, Adam D., Hwang, Wei-Ting, Fraietta, Joseph A., Davis, Megan M., Levine, Bruce L., Siegel, Don L., Stadtmauer, Edward A., Vogl, Dan T., Waxman, Adam, Rapoport, Aaron P., Milone, Michael C., June, Carl H., Melenhorst, J. Joseph
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2019
Fag:
Stimulus Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784521/
https://ncbi.nlm.nih.gov/pubmed/31575532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000600
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker